Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Organic Letters
|
February 21, 2018
Chemically Diverse Helix-Constrained Peptides Using Selenocysteine Crosslinking
Aline Dantas de Araujo, Samuel R Perry, David P Fairlie
Proceedings of the National Academy of Sciences of the United States of America
|
November 16, 2011
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma
Peter Olson, Gerald C Chu, Samuel R Perry, et al.
Organic & Biomolecular Chemistry
|
December 22, 2017
Contiguous hydrophobic and charged surface patches in short helix-constrained peptides drive cell permeability
Samuel R Perry, Timothy A Hill, Aline D de Araujo, et al.
Journal of Cell Science
|
July 14, 2018
FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models
Samantha J Stehbens, Robert J Ju, Mark N Adams, et al.
Journal of Chemical Information and Modeling
|
May 23, 2015
Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery
Samuel R Perry, Weijun Xu, Anna Wirija, et al.
ACS Chemical Biology
|
June 22, 2017
Downsizing Proto-oncogene cFos to Short Helix-Constrained Peptides That Bind Jun
Daniel Baxter, Samuel R Perry, Timothy A Hill, et al.
The Journal of Biological Chemistry
|
April 20, 2018
Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
Vaheh Oganesyan, Li Peng, Jared S Bee, et al.
Cancer Cell
|
May 19, 2010
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas
Hongwu Zheng, Haoqiang Ying, Ruprecht Wiedemeyer, et al.
Nature
|
October 25, 2008
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Hongwu Zheng, Haoqiang Ying, Haiyan Yan, et al.
Cancer Cell
|
January 15, 2016
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Organic Letters
|
February 21, 2018
Chemically Diverse Helix-Constrained Peptides Using Selenocysteine Crosslinking
Aline Dantas de Araujo, Samuel R Perry, David P Fairlie
Proceedings of the National Academy of Sciences of the United States of America
|
November 16, 2011
Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma
Peter Olson, Gerald C Chu, Samuel R Perry, et al.
Organic & Biomolecular Chemistry
|
December 22, 2017
Contiguous hydrophobic and charged surface patches in short helix-constrained peptides drive cell permeability
Samuel R Perry, Timothy A Hill, Aline D de Araujo, et al.
Journal of Cell Science
|
July 14, 2018
FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell models
Samantha J Stehbens, Robert J Ju, Mark N Adams, et al.
Journal of Chemical Information and Modeling
|
May 23, 2015
Three Homology Models of PAR2 Derived from Different Templates: Application to Antagonist Discovery
Samuel R Perry, Weijun Xu, Anna Wirija, et al.
ACS Chemical Biology
|
June 22, 2017
Downsizing Proto-oncogene cFos to Short Helix-Constrained Peptides That Bind Jun
Daniel Baxter, Samuel R Perry, Timothy A Hill, et al.
The Journal of Biological Chemistry
|
April 20, 2018
Structural insights into the mechanism of action of a biparatopic anti-HER2 antibody
Vaheh Oganesyan, Li Peng, Jared S Bee, et al.
Cancer Cell
|
May 19, 2010
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas
Hongwu Zheng, Haoqiang Ying, Ruprecht Wiedemeyer, et al.
Nature
|
October 25, 2008
p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation
Hongwu Zheng, Haoqiang Ying, Haiyan Yan, et al.
Cancer Cell
|
January 15, 2016
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y Li, Samuel R Perry, Vanessa Muniz-Medina, et al.
Page
of 2